BeOne Medicines

Meet Kristian Stubbs, our General Manager, Canada at BeOne. Driven by a personal connection to cancer, he is committed to expanding access to our innovative cancer therapies to the people who need them. Swipe to learn more. #TeamBeOne

Impact is not only measured by what we achieve, but also how we show up for others. As part of our commitment to creating a positive impact, the BeOne Care Foundation supports initiatives that eliminate barriers to accessible cancer care in underserved communities. From funding critical programs to driving disease awareness, swipe to learn how we helped to make a difference in 2025 through our Access to Cancer Care grants. #BeOneAgainstCancer #PatientsFirst

Elevating the patient voice is central to BeOne’s efforts to unite the worldwide community against cancer. Today, we are sharing an article published in @GiOncNow that highlights urgent challenges raised by patients, caregivers, and clinicians at Hope for Stomach Cancer's 4th Patient Empowerment Summit. These perspectives, many offered directly by patients, provide important guidance for the GI oncology community as we work together to close gaps in gastric cancer care. Read the article here: gioncologynow.com/page/patient-p…

🌍 It’s #RareDiseaseDay 2026! 💜 Today we stand with the 300 million people living with a rare disease. Together, we’re showing our colours, raising awareness, and inspiring change by talking about what equity means to us. 👉 Read more: go.rarediseaseday.org/NEWS

This #RareDiseaseDay we’re shining a light on the 300 million people worldwide living with a rare disease. While each rare disease is unique, there are many shared challenges, including delayed or missed diagnoses, limited care options, research and data limitations, and barriers to access. At BeOne, we’re committed to improving treatment options for those affected by rare diseases like Mantle Cell Lymphoma (MCL), a type of blood cancer. Join us in raising awareness, sharing support, and standing with the rare disease community today. #BeOneAgainstCancer #MCL

#News for #Investors and #Media: BeOne Medicines announces fourth quarter and full-year 2025 financial results and business updates. Read the full press release here: ir.beonemedicines.com/news/beone-med…

In the latest Cancer Has No Borders podcast episode, our Head of Europe, Giancarlo Benelli, discusses how growth in Europe will play a critical role for our global business. Learn more about our commitment to developing more effective and inclusive trials for patients across the region here: youtu.be/expUgmLYZ2k?si… Or listen on your favorite podcast platform: Apple: podcasts.apple.com/us/podcast/epi… Spotify: open.spotify.com/episode/0aSTyq… #BeOneAgainstCancer

“People facing cancer cling to time, clarity, and trust.” In blood cancers like chronic lymphocytic leukemia (CLL) -- step therapy, insurer delays, and coverage denials can cost patients precious time. Thank you to @CllSociety for spotlighting insurer and PBM barriers that stand between patients and the treatment their physicians prescribe.

AI is transforming how we discover, develop, and deliver medicines, and how patients navigate their care. As patients increasingly turn to #AI for health guidance, companies have a responsibility to help shape these tools thoughtfully, in partnership with patient advocacy groups and the broader cancer community. Our Co-Founder, Chairman and CEO, @johnvoyler shared perspectives on this critical inflection point for our industry in Scrip's "What Does 2026 Hold For Biopharma?" series. His insights highlight both the opportunities and responsibilities ahead, from reducing clinical trial costs to ensuring patients have access to accurate, trustworthy information when navigating their care journey. At BeOne, we're committed to leading this next era of patient-centered innovation. Read the full article here: ow.ly/qtxh50YhiAI

BeOne is supporting the first-ever clinical trial in Sub-Saharan Africa to utilize immunotherapy by supplying and distributing our PD-1 inhibitor, for investigational use, to the study. We are part of a global effort, in partnership with Obafemi Awolowo University, Lagos University Teaching Hospital, Medserve and Memorial Sloan Kettering Cancer Center, that is studying the use of immunotherapy in patients in Nigeria with mismatch-repair deficient (dMMR) colorectal cancer. Together, we’re working to advance access and transform outcomes for people living with colorectal cancer. #BeOneAgainstCancer

Cancer is complex and personal. We challenged ourselves to capture it in one word. Ours: HOPE. Whether you're a patient, survivor, caregiver, or researcher—your experience is part of this story. What's your one word? Share below. #WorldCancerDay #UnitedByUnique #BeOneAgainstCancer @uicc

More than 40 million people now use ChatGPT daily for health-related questions - and cancer patients are increasingly turning to #AI tools to help make sense of their diagnosis, lab results, and treatment options. In collaboration with @KatieCouric Media, this article outlines practical guidance to help patients and caregivers understand when AI tools can be helpful, when to turn to their doctor or an advocacy organization, and how to navigate cancer care with greater confidence. Watch to learn more, and read the full article here: katiecouric.com/health/cancer/… #BeOneAgainstCancer #AI

Season two of the Cancer Has No Borders podcast is here! In the latest episode, our SVP and Chief Medical Officer, Solid Tumors, Mark Lanasa talks about the impact of AI in our R&D processes. Watch the full episode here: youtu.be/xq8Q2VdzUG8?si… Or listen on your favorite platform: Apple: podcasts.apple.com/us/podcast/epi… Spotify: open.spotify.com/episode/4YVTCm… Amazon: amazon.com/Cancer-Has-No-… #BeOneAgainstCancer #AI

As we look ahead to 2026, our #PatientsFirst commitment remains unwavering – standing up for patients, everywhere. From day one, we’ve set out to defy the status quo, reimagining how life-changing cancer therapies are discovered, developed, and delivered to those who need them most. For us, access isn’t an aspiration – it’s an imperative. With ~2 million patients worldwide already treated with our medicines, we know this is just the beginning. #TeamBeOne

We’re not just following the science—we’re leading it. BeOne is redefining what’s possible in cancer care with a pipeline built for impact. Ready to see what’s next? Learn more: beonemedicines.com/science/resear… #BuiltToBreakThrough #BeOneInnovator #CancerHasNoBorders

#News for #Investors and #Media: BeOne is proud to present at the the 44th Annual J.P. Morgan Healthcare Conference, highlighting our continued global leadership in oncology and long-term commitment to innovation and patients worldwide. View the full press release here: ir.beonemedicines.com/news/beone-med… #JPM2026 #OncologyLeadership #BeOneInnovator

As ASCO #GI26 comes to a close, we reflect on an inspiring few days of collaboration and forward momentum in GI oncology. One of the clear highlights of the meeting was the presentation of positive Phase 3 results in patients with HER2+ GEA. Thank you to everyone who contributed! We’re looking forward to what comes next!

On Tuesday, January 13, 2026, @johnvoyler, Co-Founder, Chairman, and CEO of BeOne, will take the stage at the 44th Annual J.P. Morgan Healthcare Conference to highlight BeOne's emergence as the world’s leading oncology company with established leadership in the treatment of B-cell malignancies, an industry-leading pipeline, and a unique set of internal capabilities designed to accelerate innovation for patients around the world. 📅 Tuesday, January 13, 2026 ⏰ 7:30 AM PT / 10:30 AM ET We look forward to showcasing how the future of BeOne as a global oncology leader isn’t potential anymore — it’s happening now. Live webcast of the presentation will be available and archived here: ir.beonemedicines.com #JPM2026 #BeOneInnovator #OncologyLeadership

At this year’s ASCO #GI26 Symposium, #TeamBeOne is highlighting important Phase 3 data in GEA. Our Head of Global Medical Affairs for Solid Tumors, Nadeem Ghali, shares his take on this data from the congress floor. #FromFloorToFeed #GICancer

#News for #Investors and #Media: A late-breaking oral presentation will be presented at ASCO #GI26 featuring a Phase 3 study evaluating a combination regimen including a HER2-targeted bispecific antibody that we have licensed in Asia Pacific (excluding Japan) with and without our PD-1 inhibitor in patients with HER2+ GEA. Read the press release: ir.beonemedicines.com/news/ziihera-p…